The current financial score of Tango Therapeutics Inc is 8.22. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 42.44%.
The current valuation score of Tango Therapeutics Inc is 9.02. Its current P/E ratio is -26.20, which is -96.51% below the recent high of -0.91 and -51.26% above the recent low of -39.64.
The current earnings forecast score of Tango Therapeutics Inc is 8.83. The average price target is 45.10, with a high of 69.00 and a low of 24.00.
The current price momentum score of Tango Therapeutics Inc is 4.74. Currently, the stock price is trading between the resistance level at 25.29 and the support level at 19.92, making it suitable for range-bound swing trading.
The current institutional shareholding score of Tango Therapeutics Inc is 10.00. The latest institutional shareholding proportion is 123.32%, representing a quarter-over-quarter increase of 24.30%. The largest institutional shareholder is James Simons, holding a total of 748.30K shares, representing 0.03% of shares outstanding, with 8798.34% increase in holdings.
The current risk assessment score of Tango Therapeutics Inc is 4.81. The company's beta value is 1.17. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.